116 related articles for article (PubMed ID: 14577320)
21. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA; Wade J; Langston AA; Chauncey TR; Bruno B; Blume KG; Storb R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
[TBL] [Abstract][Full Text] [Related]
22. [Chronic graft-versus-host disease with multiple serositis after bone marrow transplantation from non-inherited maternal antigen-complementary sibling donor].
Akahane K; Inukai T; Nemoto A; Kuroda I; Minai A; Hirose K; Honna H; Goi K; Sugita K
Rinsho Ketsueki; 2010 Feb; 51(2):132-7. PubMed ID: 20379105
[TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings.
Vogelsang GB; Arai S
Bone Marrow Transplant; 2001 Jun; 27(12):1255-62. PubMed ID: 11548843
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of two case childhood acute lymphoblastic leukemia by HLA-mismatched unrelated umbilical cord blood transplantation].
Sun Z; Wang Z; Zhu W; Liu H; Liu X; Liu Z; Wang N; Pan L; Wu S; Wu J
Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):198-201. PubMed ID: 12133457
[TBL] [Abstract][Full Text] [Related]
25. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
[TBL] [Abstract][Full Text] [Related]
26. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
[TBL] [Abstract][Full Text] [Related]
27. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin.
Finke J; Schmoor C; Lang H; Potthoff K; Bertz H
J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442
[TBL] [Abstract][Full Text] [Related]
28. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
[TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation.
Mohty M; de Lavallade H; Faucher C; Bilger K; Vey N; Stoppa AM; Gravis G; Coso D; Viens P; Gastaut JA; Blaise D
Bone Marrow Transplant; 2004 Sep; 34(6):527-30. PubMed ID: 15286687
[TBL] [Abstract][Full Text] [Related]
30. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.
Onishi C; Ohashi K; Sawada T; Nakano M; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
Int J Hematol; 2010 Apr; 91(3):464-70. PubMed ID: 20217287
[TBL] [Abstract][Full Text] [Related]
31. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
[TBL] [Abstract][Full Text] [Related]
32. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation.
Hambach L; Stadler M; Dammann E; Ganser A; Hertenstein B
Bone Marrow Transplant; 2002 Jun; 29(11):903-6. PubMed ID: 12080355
[TBL] [Abstract][Full Text] [Related]
33. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
Basara N; Blau WI; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Bone Marrow Transplant; 1998 Jul; 22(1):61-5. PubMed ID: 9678797
[TBL] [Abstract][Full Text] [Related]
34. [Outcome of 46 children with refractory leukemia treated with unrelated donor hematopoietic stem cell transplantation].
Chen J; Luo CJ; Jiang H; Luo CY; Xue HL; Tang JY; Pan C; Dong L; Zhou M; Ye QD; Wang YP; Gu LJ
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):170-4. PubMed ID: 20426949
[TBL] [Abstract][Full Text] [Related]
35. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.
Minagawa K; Yamamori M; Katayama Y; Matsui T
Int J Hematol; 2012 Jul; 96(1):10-25. PubMed ID: 22592321
[TBL] [Abstract][Full Text] [Related]
36. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
37. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
38. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
Kennedy GA; Butler J; Western R; Morton J; Durrant S; Hill GR
Bone Marrow Transplant; 2006 Jun; 37(12):1143-7. PubMed ID: 16699531
[TBL] [Abstract][Full Text] [Related]
39. Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation.
Ueda Oshima M; Xie H; Zamora D; Flowers ME; Hill GR; Mielcarek MB; Sandmaier BM; Gooley TA; Boeckh MJ
Blood Adv; 2023 Apr; 7(8):1394-1403. PubMed ID: 36595478
[TBL] [Abstract][Full Text] [Related]
40. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.
Iida M; Fukuda T; Ikegame K; Yoshihara S; Ogawa H; Taniguchi S; Takami A; Abe Y; Hino M; Etou T; Ueda Y; Yujiri T; Matsui T; Okamura A; Tanaka J; Atsuta Y; Kodera Y; Suzuki R
Int J Hematol; 2011 Apr; 93(4):523-531. PubMed ID: 21465117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
